Oct. 7 at 3:08 AM
Hey @RiskCPremium, I feel your pain. I really do. I got burned by
$RLMD's prior crashes too. But it's very common for a Phase III trial to fail. It happens. It's painful, but it happens. 🤷♀️
That said, personally, I think Sergio is a fine CEO for what we need. For two reasons:
1. NDV-01 is a layup in regards to: success of trials (it's obvious going to show great efficacy), FDA approval (FDA is obviously going to bend over backwards to approve this), and market uptake (I think it's going to launch incredibly fast\well; docs are clamoring for it). It's obviously going to be very successful and be worth
$1-3B dollars, IMO.
2. Lastly, don't forget that <<SERGIO IS THE ONE>> who in-licensed NDV-01. And the terms of the deal were incredibly favorable:
$3M UPFRONT, 3M SHARES, 3% ROYALTIES. I.e. he got it for us for a song. That's a huge feat that we are all now benefiting from. You have to give him huge credit for that, IMO.
